{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:05:11Z","timestamp":1792807511884,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jgar.2025.02.001","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:27:03Z","timestamp":1739359623000},"page":"161-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["In vitro activity of ceftolozane\/tazobactam against ESBL-producing enterobacterales in China: SMART 2016\u20132019"],"prefix":"10.1016","volume":"42","author":[{"given":"Wei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.02.001_bib0001","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13017-017-0141-6","article-title":"The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections","volume":"12","author":"Sartelli","year":"2017","journal-title":"World J Emerg Surg"},{"issue":"4","key":"10.1016\/j.jgar.2025.02.001_bib0002","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijantimicag.2016.01.008","article-title":"Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013","volume":"47","author":"Jean","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.02.001_bib0003","unstructured":"World Health Organization. WHO Bacterial Priority Pathogens List, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance 2024 [cited 2025 Jan 7]. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376776\/9789240093461-eng.pdf?sequence=1."},{"key":"10.1016\/j.jgar.2025.02.001_bib0004","doi-asserted-by":"crossref","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jgar.2025.02.001_bib0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.jgar.2025.02.001_bib0006","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12941-022-00528-0","article-title":"Ceftolozane\/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)","volume":"21","author":"Khankhel","year":"2022","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2025.02.001_bib0007","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jgar.2017.04.003","article-title":"In vitro activity of ceftolozane\/tazobactam in combination with other classes of antibacterial agents","volume":"10","author":"Jacqueline","year":"2017","journal-title":"J Glob Antimicrob Re"},{"issue":"4","key":"10.1016\/j.jgar.2025.02.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01854-22","article-title":"In vitro activity of new beta-lactam-beta-lactamase inhibitor combinations and comparators against clinical isolates of gram-negative bacilli: results from the China Antimicrobial Surveillance Network (CHINET) in 2019","volume":"10","author":"Guo","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.jgar.2025.02.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01726-20","volume":"65","author":"Yang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jgar.2025.02.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02431-18","article-title":"Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa","volume":"63","author":"Yin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.02.001_bib0011","series-title":"M100 performance standards for antimicrobial susceptibility testing","author":"Lewis","year":"2023"},{"key":"10.1016\/j.jgar.2025.02.001_bib0012","unstructured":"CHINET. CHINET report 2022. http:\/\/www.chinets.com\/Document\/Index?pageIndex=0."},{"key":"10.1016\/j.jgar.2025.02.001_bib0013","unstructured":"CARSS. CARSS report 2020. http:\/\/www.carss.cn\/."},{"key":"10.1016\/j.jgar.2025.02.001_bib0014","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jgar.2022.01.029","article-title":"Epidemiology and genotypic characteristics of carbapenem resistant enterobacterales in Henan, China: a multicentre study","volume":"29","author":"Jing","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.jgar.2025.02.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221079761","article-title":"Prevalence and antibiotic resistance of Klebsiella pneumoniae in a tertiary hospital in Hangzhou, China, 2006-2020","volume":"50","author":"Lin","year":"2022","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jgar.2025.02.001_bib0016","article-title":"Global evaluation of the antibacterial activity of ceftolozane\/tazobactam against ESBLs-producing Escherichia coli and Klebsiella pneumoniae: a systematic review and meta-analysis","volume":"10","author":"Rahim Khorasani","year":"2023","journal-title":"Ther Adv Infect Dis"},{"issue":"5","key":"10.1016\/j.jgar.2025.02.001_bib0017","doi-asserted-by":"crossref","first-page":"ofaa139","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/tazobactam for treatment of severe ESBL-producing enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II study)","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2025.02.001_bib0018","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.jgar.2025.02.001_bib0019","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.02.001_bib0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijid.2022.08.003","article-title":"A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane\/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections","volume":"123","author":"Sun","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2025.02.001_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/sur.2016.261","article-title":"The Surgical Infection Society revised guidelines on the management of intra-abdominal infection","volume":"18","author":"Mazuski","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"issue":"1","key":"10.1016\/j.jgar.2025.02.001_bib0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3947\/ic.2018.50.1.67","article-title":"Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections","volume":"50","author":"Kang","year":"2018","journal-title":"Infect Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525000359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525000359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:59:32Z","timestamp":1762610372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525000359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":22,"alternative-id":["S2213716525000359"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.02.001","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftolozane\/tazobactam against ESBL-producing enterobacterales in China: SMART 2016\u20132019","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}